Based on the recent earnings conference call transcript, it is clear that the company has reported strong financial metrics, including adjusted earnings of $814 million and adjusted earnings per share of $2.45, year-over-year growth of 11% and 18% respectively. The third quarter results reflect strong core business fundamentals driven by disciplined pricing, moderate medical cost trend, and continued capital deployment.

The adjusted revenue for the third quarter was $14.9 billion, with a year-over-year decrease driven by a planned reduction in Commercial ACA insured membership, the suspension of the health insurer fee, and known Medicaid contract losses. The operating perspective shows a solid performance, with an adjusted pre-tax margin at 9.2%, a strong underwriting performance, and an adjusted expense ratio of 17.5%, showing improvement over the previous year.

The balance sheet remains strong, with a debt-to-total-capitalization ratio of approximately 39.5% and a cash flow of approximately 1.5 times net earnings. The company has also returned approximately $4.3 billion to shareholders through share repurchases and quarterly dividends.

Furthermore, the company has increased its 2017 adjusted earnings per share guidance to approximately $9.75, reflecting continued strong performance. However, the outlook for 2018 and 2019 presents challenges, as the company expects pressure on adjusted revenue and earnings due to top-line challenges, the reintroduction of the non-deductible health insurer fee, and Medicaid contract exits.

In conclusion, while the company has demonstrated strong performance in the third quarter of 2017, the outlook for 2018 and 2019 presents several challenges, which is why an 'underweight' investment stance is recommended. The top-line challenges, the reintroduction of the health insurer fee, and pressure on adjusted earnings growth suggest caution for potential investors.